

ASX ANNOUNCEMENT

16 December 2020

Respiri announces New Partnership with Pharmacy 4 Less Banner Group

Respiri Limited (ASX:RSH) (“Respiri” or the “Company”), an eHealth SaaS Company supporting respiratory health management is pleased to announce a sales and marketing partnership with the Pharmacy 4 Less group of pharmacies for the sale of wheezo™ devices commencing in early 2021 across their pharmacy network.

The partnership agreement with Pharmacy 4 Less will include a wheezo feature with CEO Mr Feras Karem on Channel 10’s Studio 10 Australian morning show. This TV promotion adds to existing activities with the Carlton Football Club’s AFLW team and former Australian Cricket Captain, Michael Clarke.

With a network of over 100 stores across Australia, the Pharmacy 4 Less group is built on a foundation of professional expertise and personal service. Respiri will support the group with a commitment to build a relevant training program focused on asthma management using wheezo.

Managing Director & CEO for Pharmacy 4 Less, Mr Feras Karem said “By bringing wheezo to the Pharmacy 4 Less stores, we demonstrate our ongoing support of asthma patients, both adults and child, and their caregivers. We are passionate in improving asthma management and patient understanding is a critical step to limiting the avoidable complications of asthma, and wheezo can assist patients to better manage their asthma.”

CEO and Managing Director of Respiri, Mr Marjan Mikel was delighted with the announcement: “The Respiri team is thrilled to have Pharmacy 4 Less selling wheezo. The group’s commitment to professional services and their community and patient focus are strongly aligned with Respiri’s values. We look forward to strong partnership with Feras and the broader Pharmacy 4 Less group as we make wheezo available to asthma patients and their caregivers.”

For further information about wheezo, follow the online link <https://wheezo.com>

- ENDS -

For further information, investors and media please contact:

Mr Marjan Mikel
CEO & Managing Director
Respiri Limited
P: +61 408 462 873
E: marjan@respiri.co

Mr Nicholas Smedley
Executive Chairman
Respiri Limited
P: +61 447 074 160
E: nicholas@respiri.co

™ wheezo is a trademark of Respiri Limited.

This ASX announcement dated 16 December 2020 has been authorised for release by the Board of Directors of Respiri Limited.

About Respi Limited

Respi is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. wheezo, Respi's innovative technology, comprises an eHealth app combined with a simple, easy to use, handheld device. wheezo is the first smart device to help improve asthma management by monitoring wheeze and documenting symptoms, signs, triggers, weather conditions and medication use. The asthma management platform also facilitates the sharing of data with caregivers, physicians and other health care professionals.

Respi's mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respi Limited's operations are based in Melbourne, Australia.

For additional information about Respi and its products, please visit www.respi.co

About wheezo

Developed in Australia, with the support of respiratory specialists and other healthcare professionals, the innovative wheezo device analyses breath sounds for wheeze, and the eHealth App assists patients with managing their asthma by tracking symptoms, triggers, medication use and geo-specific weather conditions. The platform has been designed to extend asthma management beyond the clinic and make it easy to share information with doctors and make appropriate adjustments to asthma action plans. Better active management may lead to better outcomes and improved quality of life for the asthma patient.

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on Respi current expectations, estimates and projections about the industry in which Respi operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respi, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Respi cautions shareholders and prospective shareholders not to place undue reliance on these forward looking statements, which reflect the view of Respi only as of the date of this release. The forward looking statements made in this announcement relate only to events as of the date on which the statements are made. Respi will not undertake any obligation to release publicly any revisions or updates to these forward looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.